garetosmab-grts

FDA Drug Profile — Pasatru

garetosmab-grts is listed in the FDA National Drug Code directory with 1 NDC code, marketed under brand name including Pasatru. Available dosage form: injection, solution, concentrate.

Drug details

Generic Name
garetosmab-grts
Brand Names
Pasatru
Application Number
BLA761508
Sponsor
Regeneron Pharmaceuticals, Inc.
NDC Codes
1
Dosage Forms
INJECTION, SOLUTION, CONCENTRATE
Routes
INTRAVENOUS
Active Ingredients
GARETOSMAB

Indications and Usage

1 INDICATIONS AND USAGE PASATRU is indicated to reduce formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). PASATRU is an activin signaling inhibitor indicated to reduce formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.